Ranitidine

Introduction Overview

Generic Name

ranitidine

Brand Name

Zantac

Dosage Form

oral tablets, oral syrup, effervescent tablets, intravenous injection

Drug Class

H2 antagonists (histamine-2 receptor blockers)

Pharmacokinetics

Absorption: Ranitidine is rapidly absorbed following oral administration, with bioavailability approximating 50%. Peak plasma concentrations typically occur within 1 to 3 hours post-dose. It demonstrates linear pharmacokinetics over therapeutic doses. Oral absorption is affected minimally by food intake; however, food may slightly delay time to peak concentration without affecting overall exposure. The rate and extent of absorption contribute to its onset of action, typically within 1 hour after administration.

Distribution: Once absorbed, ranitidine is moderately distributed throughout body tissues and fluids, with an apparent volume of distribution of approximately 2.5-3.0 L/kg. It crosses the placental barrier and is excreted in breast milk. Plasma protein binding is relatively low (around 15%), allowing for significant free drug availability. Ranitidine accumulates in gastric mucosa, which may relate to its therapeutic effect.

Metabolism: Ranitidine is partially metabolized in the liver, primarily via N-oxidation and S-oxidation pathways. Hepatic metabolism accounts for roughly 30-40% of the administered dose, producing several inactive metabolites. Metabolic clearance may be reduced in patients with hepatic impairment, necessitating dose adjustment. No significant induction or inhibition of metabolic enzymes by ranitidine has been reported.

Elimination: The primary route of elimination is renal excretion, with approximately 30-70% of an administered dose excreted unchanged in urine. The elimination half-life ranges from 2.5 to 3.0 hours in subjects with normal renal function. In renal impairment, elimination half-life is prolonged, requiring accumulation monitoring and possible dose modification. Fecal excretion accounts for a minor portion of the drug. Hemodialysis can partially remove ranitidine from circulation.

Overall, the pharmacokinetics of ranitidine make it suitable for twice-daily dosing. The kinetics can be significantly altered by renal or hepatic dysfunction, impacting both safety and efficacy profiles.

Dosage Forms

Available Dosage Forms:
- Oral tablets (75 mg, 150 mg, 300 mg)
- Effervescent tablets (150 mg, 300 mg) that must be dissolved in water before administration
- Oral syrup or solution (15 mg/mL)
- Intravenous (IV) injection solution (25 mg/mL)

Dosages for Adults and Adolescents:
- For active duodenal ulcer: 150 mg orally twice daily or 300 mg once daily at bedtime for 4 to 8 weeks
- For maintenance therapy: 150 mg once daily at bedtime
- For gastric ulcer: 150 mg twice daily for 6 to 8 weeks
- For GERD: 150 mg twice daily for 6 to 12 weeks, extended if necessary
- Zollinger-Ellison syndrome: Initial doses often start at 150 mg twice daily and titrated up as needed, with total daily doses ranging from 300 mg to 6 grams per day divided doses

Specific Patient Populations:
- Renal Impairment: Dose adjustment recommended; for creatinine clearance <50 mL/min, dosing frequency or dose should be reduced to avoid accumulation
- Hepatic Impairment: Use with caution; reduction in dose or increased dosing interval may be necessary
- Pediatrics: Although less commonly used now, dosing has been institution-specific historically; caution advised due to limited data
- Elderly: Often requires dose adjustment due to decreased renal function

Clinical guidelines recommended administration with or without food depending on patient tolerability; effervescent formulations require dissolution prior to administration. Due to removal from several markets, alternative agents are now preferred, but dosing historically was well defined for diverse acid-related gastrointestinal conditions.

Mechanism Of Action

Ranitidine is a selective histamine H2 receptor antagonist that competitively inhibits histamine at H2 receptors on gastric parietal cells. By blocking these receptors, ranitidine effectively suppresses basal and stimulated gastric acid secretion. This inhibition reduces the volume and acidity of gastric secretions, creating an environment conducive to healing of ulcers and reduction of acid-related symptoms.

On a molecular level, H2 receptors are G protein-coupled receptors that stimulate adenylate cyclase activity, increasing intracellular cyclic AMP, which promotes activation of the proton pump (H+/K+-ATPase) that secretes acid into the stomach lumen. Ranitidine binding prevents receptor activation, leading to reduced cyclic AMP levels and subsequent downregulation of proton pump activity.

Unlike proton pump inhibitors (PPIs) that irreversibly inhibit the proton pump, ranitidine’s blockade of H2 receptors is reversible and competitive. Therefore, ranitidine induces a dose-dependent and rapid onset reduction in acid secretion but may be less effective for severe acid suppression required in some conditions. It can inhibit nocturnal acid secretion effectively but may be less potent during meal-stimulated secretion.

Clinical studies have demonstrated ranitidine’s effectiveness in healing gastric and duodenal ulcers and in controlling symptoms of gastroesophageal reflux disease (GERD) by reducing intragastric acidity and improving mucosal integrity. The drug’s ability to inhibit secretions stimulated not only by histamine but also by gastrin and acetylcholine indirectly contributes to its therapeutic efficacy. Research comparing ranitidine to other H2 blockers shows comparable efficacy but with fewer drug interactions and a favorable safety profile prior to its market withdrawal due to impurity concerns.

Pharmacological Actions

Selective competitive inhibition of histamine H2 receptors on gastric parietal cells.
Reduction of basal and stimulated gastric acid secretion.
Decrease in gastric volume and acidity, promoting mucosal healing.
Inhibition of nocturnal acid secretion more effectively than daytime postprandial secretion.
Partial blockade of gastrin and acetylcholine mediated acid production via H2 receptor inhibition.
Reduction in pepsin secretion secondary to decreased acid output.
Improvement of symptoms in acid-related gastrointestinal conditions such as GERD.
Minimal inhibition of cytochrome P450 enzymes, resulting in low potential for metabolic drug interactions.
Rapid onset of action typically within one hour of oral administration.
Allows healing of gastric and duodenal ulcers by lowering aggressive acid effects.
Used as an adjunct to prevent stress ulcers in critically ill patients.
Potent acid suppression compared to older antihistamines without anticholinergic effects.
Well tolerated with limited central nervous system penetration.

Therapeutic Or Clinical Uses

Treatment and prevention of duodenal ulcers.
Treatment and prevention of gastric ulcers.
Management of gastroesophageal reflux disease (GERD) and erosive esophagitis.
Treatment of Zollinger-Ellison syndrome and other hypersecretory conditions.
Prevention of stress-related mucosal bleeding in critically ill patients.
Treatment of benign gastric ulcers of various etiologies.
Off-label use for treatment of pathological hypersecretory conditions.
Supportive therapy in Barrett’s esophagus to reduce acid exposure.
Relief of symptoms associated with acid indigestion, heartburn, and sour stomach (historically OTC use).
Adjunctive therapy combined with antibiotics for Helicobacter pylori eradication (historically).
Reduction of acid secretion to facilitate healing of erosive esophagitis.
Management of Zollinger-Ellison syndrome through acid suppression to prevent ulceration.
Used to control nocturnal acid secretion to improve patient quality of life.
Prevention of recurrent ulcers post-healing in long-term maintenance therapy.

Side Or Adverse Effects

Common gastrointestinal side effects include nausea, vomiting, diarrhea, and constipation.
Headache and dizziness reported in some patients.
Rare occurrences of hepatocellular injury with jaundice and elevated liver enzymes.
Potential for hypersensitivity reactions including rash, urticaria, and pruritus.
Elevation of serum creatinine and altered renal function in susceptible patients.
Very rare cases of hematologic abnormalities such as thrombocytopenia, leukopenia, or agranulocytosis.
Possible gynecomastia and impotence in long-term use due to histamine receptor effects.
Central nervous system effects such as confusion or hallucinations, mainly in elderly or renal impairment cases.
Allergic reactions including anaphylaxis, angioedema, and anaphylactoid reactions reported infrequently.
Increased risk of pneumonia due to decreased gastric acidity and altered bacterial flora.
Injection site reactions with IV use including pain and thrombophlebitis.
Rare reports of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Fatigue and malaise reported in post-marketing surveillance.
Potential for drug-induced hepatitis with rise in transaminases during therapy.
Possible alteration in vitamin B12 absorption with prolonged therapy, leading to deficiency.

Precautions

Avoid use in patients with known hypersensitivity to ranitidine or other H2 antagonists.
Use cautiously in patients with renal impairment with dose adjustment to prevent accumulation.
Monitor liver function tests in patients with hepatic dysfunction during prolonged therapy.
Consider differential diagnoses for chest pain, as heartburn may mimic myocardial infarction symptoms.
Avoid abrupt discontinuation of prescription ranitidine without consultation to prevent symptom rebound.
Pregnancy and breastfeeding: consult healthcare provider due to limited data, although ranitidine was previously considered relatively safe.
Use caution in patients with porphyria as ranitidine may exacerbate the condition.
Caution with co-administration of drugs that require gastric acidity for absorption due to reduced bioavailability.
Avoid alcohol consumption during treatment to minimize gastrointestinal mucosal damage.
Ranitidine effervescent tablets and granules must be fully dissolved prior to ingestion to avoid irritation.
Monitor elderly patients closely due to increased sensitivity and renal elimination changes.
Patients with symptoms of infection or unexplained weight loss should be evaluated for gastric malignancy prior to therapy.
Avoid concomitant use of ranitidine with drugs that prolong QT interval without medical supervision.
Patient counseling on recognition and reporting of signs of allergic reactions is essential.
Discontinue if severe skin reactions or hepatic dysfunction develop.

Warnings

Ranitidine has been withdrawn from the United States market due to detection of NDMA (N-Nitrosodimethylamine), a probable human carcinogen, in drug formulations.
Use may increase the risk of developing pneumonia due to alteration of gastric flora from acid suppression.
Signs of severe allergic reactions including anaphylaxis require immediate medical attention.
Heartburn symptoms can mimic heart attack; seek urgent care for chest pain with associated cardiac symptoms.
Prolonged use can mask symptoms of gastric cancer; patients with persistent symptoms beyond treatment duration should be evaluated further.
Do not use if allergic to ranitidine or other H2 antagonists.
Potential risk of drug accumulation and toxicity in renal impairment necessitates monitoring.
Intravenous administration requires monitoring for local adverse effects such as thrombophlebitis.
Do not combine with other acid suppressive agents unless directed by healthcare provider.
Avoid in patients with severe hepatic impairment without specialist guidance.
Patients should be counseled on the importance of adherence; incomplete treatment of ulcers may lead to complications.
Risk of vitamin B12 malabsorption with long-term use exists and monitoring may be necessary.
The presence of NDMA impurities led to recalls and market withdrawal internationally.
Discontinue ranitidine immediately if jaundice, severe abdominal pain, or unexplained systemic symptoms occur.
FDA recommends alternative therapies for acid-related disorders given safety concerns.

Contraindication

Known hypersensitivity or allergy to ranitidine or any component of the formulation.
Concomitant use with other drugs known to contain NDMA impurities where risk of cumulative exposure exists.
Patients with acute porphyria due to possibility of exacerbation.
Use in patients with gastric malignancy not confirmed or ruled out prior to treatment initiation.
Severe hepatic impairment without medical supervision.
Use in patients demonstrating previous idiosyncratic adverse reactions to H2 receptor antagonists.
Known severe renal failure without appropriate dose adjustment and monitoring.
Patients with unexplained persistent abdominal symptoms where diagnosis is uncertain.
Children and neonates unless prescribed by a specialist with clear indication (off-label).
Concomitant use with drugs highly dependent on stomach pH for absorption without alternative strategies.
Use during pregnancy only if clearly needed and benefit outweighs potential risk.
Use in breastfeeding women without medical advice given limited safety data.
Concomitant administration with other agents withdrawn for safety reasons involving carcinogenic impurities.

Drug Interactions

May reduce the absorption of drugs dependent on gastric pH such as ketoconazole, itraconazole, and atazanavir.
Minimal effect on cytochrome P450 enzymes, so fewer metabolic drug interactions compared to other acid suppressants.
Concurrent use with antacids generally safe but spacing administration recommended to prevent absorption interference.
May enhance effects of warfarin by reducing vitamin K production through altered gut flora.
Potential interaction with procainamide, leading to increased plasma levels requiring monitoring.
Concomitant use with sucralfate may reduce ranitidine absorption; stagger administration times.
Possible increased bioavailability of valproic acid when coadministered with ranitidine.
No significant interaction with theophylline but close monitoring advised due to altered gastric pH.
Potential interaction with digoxin leading to altered absorption; monitor digoxin levels accordingly.
May affect absorption of calcium carbonate; administration timing should be optimized.
Co-administration with alcohol should be avoided due to increased risk of gastrointestinal side effects.
Concurrent use with other gastric acid suppressants requires careful clinical consideration.
Rare interactions reported with anti-HIV protease inhibitors due to pH-dependent solubility changes.
Interactions with herbal supplements such as St. John's Wort not well documented; caution advised.
May alter intestinal flora affecting absorption or metabolism of concomitant antimicrobial agents.

Preparations Of The Drug

Oral tablets: 75 mg, 150 mg, and 300 mg immediate-release film-coated tablets.
Effervescent tablets available in 150 mg and 300 mg strengths that require dissolution in water before ingestion.
Oral syrup formulation: 15 mg/mL concentrated solution for pediatric or difficulty swallowing patients.
Intravenous injection solution: sterile, preservative-free 25 mg/mL ampules for hospital use to treat acute conditions.
Ranitidine granules and powders for oral suspension allowed compounding; dosage individualized by prescribing physician.
Combination preparations with antacids have historically been available but are less common currently.
Sterile injectable formulations carefully preserved in vials or ampules for parenteral administration.
Formulations were manufactured under strict GMP conditions but now mostly withdrawn internationally due to impurity concerns.
Packaging includes child-resistant containers with clear patient instructions for preparation and administration.
Previously available over-the-counter in some countries in low-dose oral formulations for symptomatic relief.
Supplementary formulations included multi-dose bottles for liquid preparations with calibrated dosing syringes.
Effervescent preparations designed to improve patient compliance where swallowing tablets is difficult.
Manufacturing details included batch testing for stability and impurity levels in compliance with regulatory standards.
Patient information leaflets accompany products highlighting proper use, storage conditions, and warnings.
Storage recommendations: store at room temperature away from moisture, heat, and direct light to maintain drug stability.